CSL Se­qirus snaps up $30M+ BAR­DA con­tract to de­vel­op in­fluen­za vac­cine at its ex­pand­ed fa­cil­i­ty in NC

On­ly a few months af­ter ex­pand­ing its fa­cil­i­ty in Hol­ly Springs, NC, vac­cine mak­er CSL Se­qirus is putting the new lo­ca­tion to use with its lat­est con­tract.

HHS’s BAR­DA has cho­sen CSL Se­qirus to pro­duce an H5N8 A/As­trakhan virus vac­cine can­di­date for a Phase II study which is slat­ed to start in Q2 of next year. Ac­cord­ing to the com­pa­ny, the $30.1 mil­lion agree­ment will have the com­pa­ny de­liv­er a vac­cine can­di­date and spon­sor the tri­al to eval­u­ate the can­di­date along with CSL’s MF59 ad­ju­vant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER